|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0005516,
umls-concept:C0007634,
umls-concept:C0017262,
umls-concept:C0026764,
umls-concept:C0030705,
umls-concept:C0032854,
umls-concept:C0033325,
umls-concept:C0040715,
umls-concept:C0185117,
umls-concept:C0332281,
umls-concept:C0332293,
umls-concept:C0599718,
umls-concept:C0599813,
umls-concept:C0599893,
umls-concept:C1328050,
umls-concept:C1334863,
umls-concept:C1522702,
umls-concept:C1561558,
umls-concept:C2911684
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
2007-11-16
|
|
pubmed:abstractText |
Lack of CD56 expression was reported to be associated with a poor prognosis in multiple myeloma (MM) patients treated with conventional chemotherapy. Aim of our retrospective study was to analyse whether CD56 expression on MM cells reveals as a prognostic factor in patients treated with high-dose chemotherapy. MM cells of 99 patients prior to treatment with high-dose chemotherapy were analysed for CD56 expression by flow cytometry. Multivariable analysis of event-free survival in these patients showed no statistically significant difference between the CD56(-) (n=28) and the CD56(+) (n=71) group. The lack of CD56 expression on MM cells of these patients correlated significantly with the presence of translocation (11;14) (t(11;14)) (estimated correlation coefficient=0.655 95%, confidence interval (0.481; 0.779)). In summary, our results indicate that lack of CD56 expression on MM cells is not a prognostic marker in patients treated with high-dose chemotherapy, but is associated with t(11;14).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
0268-3369
|
|
pubmed:author |
pubmed-author:BennetCC,
pubmed-author:CremerF WFW,
pubmed-author:GoldschmidtHH,
pubmed-author:HeissCC,
pubmed-author:HoA DAD,
pubmed-author:HorzRR,
pubmed-author:HundemerMM,
pubmed-author:JauchAA,
pubmed-author:KleinUU,
pubmed-author:MoonJJ,
pubmed-author:RaabM-SMS
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
40
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1033-7
|
|
pubmed:meshHeading |
pubmed-meshheading:17891186-Adult,
pubmed-meshheading:17891186-Aged,
pubmed-meshheading:17891186-Antigens, CD56,
pubmed-meshheading:17891186-Biological Markers,
pubmed-meshheading:17891186-Chromosomes, Human, Pair 11,
pubmed-meshheading:17891186-Chromosomes, Human, Pair 17,
pubmed-meshheading:17891186-Disease-Free Survival,
pubmed-meshheading:17891186-Dose-Response Relationship, Drug,
pubmed-meshheading:17891186-Female,
pubmed-meshheading:17891186-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:17891186-Humans,
pubmed-meshheading:17891186-Male,
pubmed-meshheading:17891186-Melphalan,
pubmed-meshheading:17891186-Middle Aged,
pubmed-meshheading:17891186-Multiple Myeloma,
pubmed-meshheading:17891186-Myeloablative Agonists,
pubmed-meshheading:17891186-Retrospective Studies,
pubmed-meshheading:17891186-Translocation, Genetic,
pubmed-meshheading:17891186-Transplantation, Autologous
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Lack of CD56 expression on myeloma cells is not a marker for poor prognosis in patients treated by high-dose chemotherapy and is associated with translocation t(11;14).
|
|
pubmed:affiliation |
Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
